Mostrar registro simples

dc.contributor.authorChaudhuri, K. Ray
dc.contributor.authorKovács, Norbert
dc.contributor.authorPontieri, Francesco E.
dc.contributor.authorAldred, Jason
dc.contributor.authorBourgeois, Paul
dc.contributor.authorDavis, Thomas L.
dc.contributor.authorCubo Delgado, Esther 
dc.contributor.authorAnca-Herschkovitsch, Marieta
dc.contributor.authorIansek, Robert
dc.contributor.authorSiddiqui, Mustafa S.
dc.contributor.authorSimu, Mihaela
dc.contributor.authorBergmann, Lars
dc.contributor.authorBallina, Mayra
dc.contributor.authorKukreja, Pavnit
dc.contributor.authorLadhani, Omar
dc.contributor.authorJia, Jia
dc.contributor.authorStandaert, David G.
dc.date.accessioned2024-03-15T09:40:13Z
dc.date.available2024-03-15T09:40:13Z
dc.date.issued2023-07
dc.identifier.issn1877-7171
dc.identifier.urihttp://hdl.handle.net/10259/8834
dc.description.abstractBackground: Levodopa-carbidopa intestinal gel (LCIG) improves motor and non-motor symptoms in patients with advanced Parkinson’s disease (aPD). Objective: To present the final 36-month efficacy and safety results from DUOGLOBE (DUOdopa/Duopa in Patients with Advanced Parkinson’s Disease – a GLobal OBservational Study Evaluating Long-Term Effectiveness; NCT02611713). Methods: DUOGLOBE was an international, prospective, long-term, real-world, observational study of patients with aPD initiating LCIG in routine clinical care. The primary endpoint was change in patient-reported “Off” time to Month 36. Safety was assessed by monitoring serious adverse events (SAEs). Results: Significant improvements in “Off” time were maintained over 3 years (mean [SD]: –3.3 hours [3.7]; p < 0.001). There were significant improvements to Month 36 in total scores of the Unified Dyskinesia Rating Scale (–5.9 [23.7]; p = 0.044), Non-Motor Symptoms Scale (–14.3 [40.5]; p = 0.002), Parkinson’s Disease Sleep Scale-2 (–5.8 [12.9]; p < 0.001), and Epworth Sleepiness Scale (–1.8 [6.0]; p = 0.008). Health-related quality of life and caregiver burden significantly improved through Months 24 and 30, respectively (Month 24, 8-item Parkinson’s Disease Questionnaire Summary Index, –6.0 [22.5]; p = 0.006; Month 30, Modified Caregiver Strain Index, –2.3 [7.6]; p = 0.026). Safety was consistent with the well-established LCIG profile (SAEs: 54.9% of patients; discontinuations: 54.4%; discontinuations due to an adverse event: 27.2%). Of 106 study discontinuations, 32 patients (30.2%) continued LCIG outside the study. Conclusion: DUOGLOBE demonstrates real-world, long-term, reductions in motor and non-motor symptoms in patients with aPD treated with LCIG.en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherIOS Pressen
dc.relation.ispartofJournal of Parkinson's Disease. 2023, V. 13, n. 5, p. 769-783en
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectDUOGLOBEen
dc.subjectParkinson’s diseaseen
dc.subjectLevodopa-carbidopa intestinal gelen
dc.subjectDyskinesiaen
dc.subjectReal-world dataen
dc.subject.otherSistema nervioso-Enfermedadeses
dc.subject.otherNervous system-Diseasesen
dc.subject.otherMedicinaes
dc.subject.otherMedicineen
dc.subject.otherNeurologíaes
dc.subject.otherNeurologyen
dc.titleLevodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Resultsen
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://content.iospress.com/articles/journal-of-parkinsons-disease/jpd225105es
dc.identifier.doi10.3233/JPD-225105
dc.identifier.essn1877-718X
dc.journal.titleJournal of Parkinson's Diseaseen
dc.volume.number13es
dc.issue.number5es
dc.page.initial769es
dc.page.final783es
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Arquivos deste item

Thumbnail

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples